

BASILEA PHARMACEU

ISIN: CH0011432447 WKN: 1143244 Asset Class: **Stock**

Company

2024/07/16 13:37:49



Price

41.75 CHF

Difference ▲ 5.16%(2.05)



Contact Details

BASILEA PHARMACEUTICA
AG

Tel: +41-61-606-11-11

--

Fax: +

Hegenheimerweg 167b

Web:

4123 Allschwil

<http://www.basilea.com>

E-mail: info@basilea.com

Company Profile

Basilea Pharmaceutica AG engages in the development and commercialization of pharmaceutical products. Its products include antifungals and antibiotics. The company was founded on October 17, 2000, and is headquartered in Allschwil, Switzerland.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	152,145,000		175,364,000		241,066,000	
Common stock capital		13,100,000		13,093,000		12,992,000
Fixed assets	21,144,000		45,484,000		6,201,000	
Equity capital of a company		-10,003,000		-20,715,000		-58,607,000
Cash and cash equivalents	12,489,000		36,567,000		54,953,000	
Accrued liabilities		15,149,000		8,337,000		24,986,000
Other assets	-		-		-	
Current liabilities		47,592,000		74,850,000		174,408,000
Prepayments and accrued income		-		-		-
Non-current liabilities		135,700,000		166,713,000		131,466,000
Different income		-		-		-
Other liabilities		9,460,000		10,693,000		11,926,000
Total assets	173,289,000	173,289,000	220,848,000	220,848,000	247,267,000	247,267,000

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	147	154	154
Equity ratio	-5.77%	-9.38%	-23.70%
Debt-equity ratio	-1,832.37%	-1,166.13%	-521.91%

Others

	2023	2022	2021
Tax Expense Rate	0.10%	-0.37%	-0.54%

BASILEA PHARMACEU

ISIN: CH0011432447 WKN: 1143244 Asset Class: **Stock**

Income statement

	2023	2022	2021
Turnover	157,634,000	147,765,000	148,122,000
Net income	10,451,000	12,147,000	-6,831,000
EBIT	24,967,826	23,386,298	4,313,539
Operating income before taxes	10,461,000	12,102,000	-6,794,000
Cash Flow	14,245,000	7,056,000	-32,020,000
Net interest income	-13,867,000	-10,685,000	-10,997,000
Research and development expenses	77,852,000	73,804,000	93,157,000
Income taxes	10,000	-45,000	37,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	1,100,543	984,748	987,127

Board of Directors

Alf Gunnar Martin Nicklasson	Member of the administrative board
Carole Sable	Member of the administrative board
Nicole Onetto	Member of the administrative board
Thomas Werner	Member of the administrative board
Leonard Kruimer	Member of the administrative board
Domenico Scala	Chairman of the administrative board

Members of Management Board

David Veitch	Chairman of Managing Board
Gerrit Hauck	Member of Executive Committee
Laurenz Kellenberger	Member of Executive Committee
Marc Engelhardt	Member of Executive Committee
Adesh Kaul	Member of Executive Committee